Orilanolimab Biosimilar - Research Grade

Human

FCGRT

>1mg/ml

IgG4 - kappa

CHO Cells

Batoclimab Biosimilar - Research Grade (ICH5049), Nipocalimab Biosimilar - Research Grade (ICH5050), Rozanolixizumab Biosimilar - Research Grade (ICH5051), Efgartigimod Biosimilar - Research Grade (ICH5223)

https://www.imgt.org/mAb-DB/

ICH3002

P55899

2217

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of orilanolimab, an anti-FcRn (neonatal Fc receptor) monoclonal antibody, supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Built as a human IgG4-kappa molecule directed against the FCGRT-encoded alpha chain of FcRn, it is intended to reproduce the target-binding behaviour of the originator for laboratory investigation of FcRn biology and antibody-recycling pathways. Typical research applications include use as a binding and blocking reference standard, a positive control in FcRn-interaction and IgG-homeostasis assays, a comparator in biosimilar or developability workflows, and a tool for probing FcRn-mediated IgG and albumin transport in vitro. The material is offered at low-endotoxin research grade (<1 EU/mg), with ultra-low-endotoxin (<0.5 EU/mg) and in-vivo-standard preparations available, and can be produced in bulk milligram-to-gram quantities to support screening, formulation, and preclinical mechanistic studies. It carries no fluorophore, enzyme, or other conjugate. FCGRT encodes the alpha (heavy) chain of the neonatal Fc receptor (FcRn), an MHC class I-like glycoprotein that associates non-covalently with beta-2-microglobulin. FcRn is the central regulator of immunoglobulin G and serum albumin homeostasis. In a pH-dependent manner, it binds the Fc region of IgG and albumin within acidified endosomes (around pH 6), diverting them away from lysosomal degradation and recycling them back to the cell surface, where near-neutral pH triggers their release into circulation. This salvage pathway gives IgG and albumin their unusually long serum half-lives. FcRn also mediates transcytosis across epithelial and endothelial barriers, including maternal-fetal IgG transfer across the placenta, and contributes to antigen presentation. Blocking FcRn accelerates catabolism of circulating IgG, including pathogenic autoantibodies, which is the therapeutic rationale behind anti-FcRn antibodies in autoimmune disease.

FcRn, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, IgG receptor FcRn large subunit p51

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Orilanolimab (anti-FCGRT) Biosimilar

Q: Is the Orilanolimab biosimilar available in bulk or gram quantities?

A: Yes — the Orilanolimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Orilanolimab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Orilanolimab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Orilanolimab that binds FCGRT; for research use only (RUO).